Covidh Technologies Limited Stock Price Today (NSE: COVIDH)

Covidh Technologies Limited

143.90+0.00 (+0.00%)
Market Closed

Fundamental Score

...

Covidh Technologies Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Covidh Technologies Limited share price today is 143.90, up +0.00% on NSE/BSE as of 1 August 2026. Covidh Technologies Limited (COVIDH) is a Small-cap company in the Computers - Software & Consulting sector with a market capitalisation of 121.01 (Cr). The 52-week high for COVIDH share price is 143.90 and the 52-week low is 3.07. At a P/E ratio of 465.42x, COVIDH is currently trading above its industry average P/E of 22.33x. The company has a Return on Equity (ROE) of 6.38% and a debt-to-equity ratio of 0.20.

Covidh Technologies Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
143.90
Low
129.17
Volume
2.5K
Change
+11.39%

Covidh Technologies Limited share price chart: 11.39% return over the past month. 52-week high ₹143.90, 52-week low ₹3.07.

Covidh Technologies Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
143.90143.90143.90143.901.00 (Cr)
143.90143.90143.90143.90941.00 (Cr)
143.90143.90143.90143.900.00 (Cr)
143.90143.90143.90143.9030.00 (Cr)
143.90143.90143.90143.90968.00 (Cr)
143.90143.90143.90143.90129.00 (Cr)
143.90143.90143.90143.90119.00 (Cr)
143.90143.90143.90143.901.05K (Cr)
143.90143.90143.90143.901.20K (Cr)
143.90143.90143.90143.909.90K (Cr)

Covidh Technologies Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
131.75143.90131.75143.90+9.22%
77.49129.1877.49129.18+66.71%
77.4977.4977.4977.49+0.00%
56.2677.4956.2677.49+37.74%
38.6955.1638.6955.16+42.57%
26.1237.9426.1237.94+45.25%
17.3125.1117.3125.11+45.06%
11.2916.9811.2916.98+50.40%
8.1411.078.1411.07+36.00%
6.607.996.607.99+21.06%
4.446.484.446.48+45.95%
3.134.363.134.36+39.30%

AI Research Briefing

Powered by Gemini · 2026-08-01

A shell-company reverse merger pump disguised as a tech stock, where 465x P/E leaves zero margin for execution error.

Research Confidence
4.0/10Low
OPERATOR-DRIVENVertical breakout with 6M gain of 583.61% and 1Y gain of 6211.4%.Extremely expensive at 465.42x P/E vs industry 22.33x.

WHAT'S HAPPENING NOW (last 2-4 weeks)

The corporate restructurings follow an April 2026 postal ballot and June 26, 2026 corrigendum for a preferential share swap to acquire 100% of iSERA Biological Limited, alongside changing the company name to iSERA Lifesciences Limited. Standalone Q4 FY26 net profit surged 139.13% YoY to ₹0.55 Cr against ₹0.23 Cr in the prior period.

CORE STORY (THE REAL GAME)

This is not a software consulting play; it is a backdoor reverse merger asset injection trade. Legacy IT operations (5Y sales CAGR down 8.58%) are being shell-swapped for a biological science business, backed by a massive promoter stake increase of 55.06% to 58.63%.

Why Now
  • Preferential share swap announced to acquire 100% stake in iSERA Biological Limited.
  • Name change to iSERA Lifesciences Limited driving speculative pivot narrative.
  • Promoter stake surged 55.06% to 58.63% alongside Q4 FY26 net profit of ₹0.55 Cr.
Potential Catalysts
  • Definitive regulatory and shareholder approval for iSERA Biological share swap.
  • First combined earnings readout post-merger integration.
  • Severe profit-booking due to extreme 465x P/E valuation.
Key Risks
  • Severe micro-cap illiquidity risk with zero FII/DII participation.
  • 5-year cumulative Free Cash Flow sits deep in the red at ₹-7.23 Cr.
  • Massive valuation stretch at 465.42x P/E vs industry average 22.33x.
Institutional Activity

Promoter increased stake by 55.06% to 58.63%; FII and DII holdings remain at 0.0%.

Macro Context

Indian IT consulting growth (+24% cloud expansion) is irrelevant here as the company pivots completely into biotech.

Order Book / Expansion

Executing 100% equity acquisition of iSERA Biological Limited via share swap.

Cash Flow Quality

No, 5-year Free Cash Flow stands negative at ₹-7.23 Cr.

3–6 Month Outlook

Subsequent 3-6 month performance hinges entirely on post-merger integration of iSERA Biological. Extreme downside risk exists if execution fails to justify the inflated valuation.

Primary Thesis Risk

Execution failure or regulatory rejection of the iSERA Biological share swap.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Poor

Return on Equity (ROE)

6.38%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

5.95%

Returns generated on total capital deployed

Oper. Profit Margin (5Y Avg)

N/A

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Covidh Technologies Limited Valuation Check

Poor

Price to Earnings (P/E)

465.42x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

22.33x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

58.63%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

139.13%

Net profit growth vs same quarter last year

Revenue Growth (Quarterly YoY)

N/A

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

-8.58%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

36.78%

Earnings per share growth over 5 years

Poor

Net Profit Growth (5-Year CAGR)

-31.94%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.20x

Total debt ÷ equity. Below 0.5 = financially healthy

Interest Coverage Ratio

N/A

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-7.23 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Covidh Technologies Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of COVIDH across key market metrics for learning purposes.

Positive Indicators

5 factors identified

Robust Profit Growth (139.13%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Excellent EPS Growth (36.78% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Conservative Debt Levels (D/E: 0.20)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Balanced Promoter Holding (58.63%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

7 factors identified

Below-Average Return on Equity (6.38%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (5.95%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Premium Valuation Risk (P/E: 465.42x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

Limited Growth History (-8.58% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Stagnant Profit Growth (-31.94% CAGR)

Observation: Limited 5-year profit growth trajectory.

Analysis: Low profit growth may indicate scalability challenges or market maturity.

Negative Free Cash Flow (₹-7.23 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Covidh Technologies Limited vs Computers - Software & Consulting Peers

Peer Comparison - Computers - Software & Consulting

Compare Covidh Technologies Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
26.8/100
144
₹121.01
465.4
Average
6.38%
Poor
5.95%
Poor
0.2
Excellent
-31.94%
Poor
-8.58%
Poor
0.00%
65.4/100
2366
₹791945.76
14.8
Average
51.81%
Excellent
63.03%
Excellent
0.1
Excellent
9.45%
Good
10.22%
Good
2.92%
60.4/100
1130
₹437177.23
14.5
Average
31.89%
Excellent
39.95%
Excellent
0.1
Excellent
9.29%
Good
12.20%
Good
4.46%
65.8/100
1347
₹316874.61
17.5
Average
23.98%
Excellent
30.60%
Excellent
0.1
Excellent
9.57%
Good
11.54%
Good
4.62%
Wipro Ltd...
WIPRO507685
49.2/100
176
₹173010.39
13.1
Average
15.46%
Good
17.84%
Good
0.2
Excellent
4.05%
Average
8.38%
Good
6.30%
41.9/100
1651
₹146940.68
29.4
Average
17.53%
Good
23.12%
Excellent
0.1
Excellent
2.44%
Average
8.46%
Good
3.40%
74.7/100
4381
₹120235.26
21.4
Average
23.13%
Excellent
29.60%
Excellent
0.1
Excellent
22.79%
Excellent
27.88%
Excellent
1.85%
63.8/100
5549
₹80072.30
41.5
Average
27.24%
Excellent
34.36%
Excellent
0.1
Excellent
35.85%
Excellent
28.63%
Excellent
0.69%
69.2/100
1721
₹67910.23
41.4
Average
20.64%
Excellent
23.50%
Excellent
0.1
Excellent
28.45%
Excellent
28.60%
Excellent
0.99%
Mphasis Ltd...
MPHASIS526299
46/100
2342
₹44659.24
23.6
Average
18.53%
Good
22.09%
Excellent
0.2
Excellent
9.19%
Good
10.31%
Good
2.65%
58.6/100
562
₹34454.91
23.5
Average
24.86%
Excellent
30.07%
Excellent
0.1
Excellent
18.49%
Excellent
16.49%
Excellent
2.04%

Covidh Technologies Limited Quarterly Performance

Latest quarterly metrics for COVIDH — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

N/A

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

139.13%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

-8.58%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

-31.94%

Compounded annual net profit growth over 5 years

Covidh Technologies Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for COVIDH — calculated from daily price history

100RSI 14
Overbought — RSI 100

Momentum is strong — price may be stretched. Watch for pullbacks.

SMA 50
118
▲ Price above SMA 50 — Short-term bullish
SMA 200
50
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
3K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Covidh Technologies Limited Financial Statements

Annual income statement, balance sheet and cash flow for Covidh Technologies Limited (COVIDH) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Covidh Technologies Limited

About COVIDH (Covidh Technologies Limited)

Covidh Technologies Limited is a cutting-edge solutions provider specializing in comprehensive software development and IT consulting services. Born from a vision to empower busine...sses in the digital age, COVIDH crafts bespoke software applications, implements robust cloud infrastructures, and offers strategic IT guidance to companies across diverse industries. We prioritize innovation and scalability, ensuring our clients are equipped to thrive in a rapidly evolving technological landscape. From initial concept design to seamless deployment and ongoing support, COVIDH acts as a dedicated partner, helping businesses unlock their full potential through tailored technology solutions. We are committed to leveraging the latest advancements in AI, machine learning, and data analytics to deliver exceptional results and drive significant business impact. COVIDH distinguishes itself through its unwavering focus on client-centricity and a commitment to building long-term partnerships. Our team of experienced software engineers, IT consultants, and project managers work collaboratively with clients to understand their unique challenges and objectives. This collaborative approach allows us to develop customized solutions that address specific needs and drive measurable results. We excel in providing end-to-end services, covering everything from initial business analysis and requirements gathering to software design, development, testing, and deployment. Furthermore, COVIDH offers ongoing maintenance and support to ensure our solutions remain optimized and aligned with evolving business demands. Our goal is to be a trusted technology advisor, enabling our clients to achieve their strategic goals and maintain a competitive edge. Headquartered in Hyderabad, India, COVIDH fosters a dynamic and collaborative work environment that attracts top talent in the IT industry. We are dedicated to fostering a culture of continuous learning and innovation, empowering our employees to stay ahead of the curve and deliver exceptional service. Our commitment to ethical business practices and social responsibility underpins everything we do. COVIDH strives to create a positive impact on the communities we serve and build a sustainable future. By focusing on innovation, client satisfaction, and employee growth, we are positioned to be a leader in the software development and IT consulting space, driving value for our clients and stakeholders alike.

Company Details

Symbol:COVIDH
Industry:Computers - Software & Consulting
Sector:Computers - Software & Consulting

Key Leadership

Ms. Jayshree Suresh Jain
MD & Director
Mr. Vishal Jain
Chief Financial Officer
Ms. Deepakshi -
Company Secretary & Compliance Officer

COVIDH Share Price: Frequently Asked Questions

What is the current share price of Covidh Technologies Limited?

Covidh Technologies Limited (COVIDH) trades at ₹143.90 on NSE and BSE. Market cap ₹121.01 (Cr). Educational data only.

What is the P/E ratio of Covidh Technologies Limited?

Covidh Technologies Limited has a P/E of 465.42x vs industry average 22.33x.

What is the Bull Run score for Covidh Technologies Limited?

Covidh Technologies Limited has a Bull Run score of 26.8/100 based on 25+ financial parameters.

Does Covidh Technologies Limited pay dividends?

Covidh Technologies Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Covidh Technologies Limited?

Covidh Technologies Limited has ROE of 6.38%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Covidh Technologies Limited?

Covidh Technologies Limited has debt-to-equity of 0.20.

Is Covidh Technologies Limited a good investment?

Bull Run gives Covidh Technologies Limited a score of 26.8/100. This is not investment advice — consult a SEBI-registered advisor.